An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

Evaluation of Dual Energy CT for the Detection of Gastrointestinal Carcinoids

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04993261

Enrollment

Registered

2021-08-06

Start date

2015-09-23

Completion date

2026-12-31

Last updated

2026-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoid Syndrome, Carcinoid Tumor, Digestive System Neuroendocrine Tumor G1, Metastatic Carcinoid Tumor

Brief summary

This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors. CT is an imaging technique that uses x-rays and a computer to create images of areas inside the body. Dual energy computed tomography is a technique used during routine CT scans to help obtain and process the image after the scan is complete. Doctors want to learn if dual energy computed tomography can help improve the detection of carcinoid tumors during routine CT scans.

Detailed description

PRIMARY OBJECTIVES: I. Evaluate prospectively the sensitivity and specificity of dual energy computed tomography (CT) in detecting primary gastrointestinal (GI) carcinoid. OUTLINE: Patients undergo one dual energy CT scan during scheduled CT scan.

Interventions

PROCEDUREDual-Energy Computed Tomography

Undergo dual energy CT scan

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with: clinical features of carcinoid syndrome (or) increased serum and urinary markers suggestive of carcinoid (or) endoscopic biopsy proven carcinoid (or) metastases which are biopsy proven as carcinoid. * Patient is scheduled to have a clinically indicated staging CT exam. * Patients who have signed their informed consent form to undergo the study.

Exclusion criteria

* Patients who have already had their primary GI carcinoid resected. * Contraindication to intravenous contrast agents (e.g. allergy, renal failure, dialysis, pregnancy etc.). * Pregnant patients.

Design outcomes

Primary

Measure	Time frame
Sensitivity and specificity of dual energy computed tomography in detecting primary gastrointestinal carcinoid tumors	through study completion, an average of 1 year

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORAjaykumar Morani

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 12, 2026